ALBLASSERDAM, Netherlands, Aug. 1, 2025 /PRNewswire/ — Oceanco, one of the world’s leading custom yacht builders, is entering a new chapter with Gabe Newell – founder of Valve, tech pioneer, and longtime supporter.
Over the past 15 years, under the stewardship of the Barwani family, Oceanco has delivered some of the most iconic yachts — including Kaos, Bravo Eugenia, Black Pearl and Koru. With this foundation in place, it’s time for Oceanco’s next ownership. The Barwani family will remain active in the yachting world through their continued ownership of Turquoise Yachts, the leading Turkish custom yacht builder.
Gabe Newell is not entering this world as a financier or a strategist, but as a hands-on visionary who respects the sea, the craft, and above all, the people who make it possible. He wants Oceanco to continue on what it already does best: placing people first. This is not about buying a yacht company. It’s about plugging into a team and exploring what kind of future they can create when nothing holds them back.
Human-first. Ocean-minded. Future-focused.
Welcome to Oceanco’s next journey.
IMAGES
A selection of images are available for download here
CONTACT
Paris Baloumis, Group Marketing Director
Paris.Baloumis@oceanco.mc/+31 78 69 95 399
www.builtbyoceanco.com
View original content:https://www.prnewswire.co.uk/news-releases/a-new-chapter-for-oceanco-new-shareholder-gabe-newell-302517589.html
The company launches in-house lending for global users starting at 1.9%, delivering one of the…
Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS, May 14, 2026…
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…
SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…